Ovintiv Announces Release of 2022 Sustainability Report

BioSig Technologies, Inc. (OTCQB:BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that Kenneth Londoner, Chairman and Chief Executive Officer, is to speak at the Digital Silver Forum in Helsinki, Finland, on November 28, 2017.
Digital Silver Forum is a one-day event designed to bring together a community of innovators, public policy experts, corporate leaders and entrepreneurs to connect and explore opportunities that emerge from combining growing digital capability with the needs and demands of aging populations. The forum is co-organized by the government of Finland, known for its pioneering policies for the aging population, and Global Coalition on Aging (GCOA), world’s leading organization which provides businesses with strategic insights, best practices and access to a growing network of influencers to maximize the potential of the aging population.
Kenneth Londoner, Chairman & Chief Executive Officer of BioSig Technologies, Inc., has been invited as a speaker for ‘Financing the 21st Century and Beyond’ panel, which will discuss strategies to finance innovation for development of new products and services in the changing demographics. Other panels held during the Forum include sessions on Artificial Intelligence and machine learning, market diversity and remote care delivery.
Mr. Londoner will also be on the panel of judges during the pitching session, where nine startups will showcase their innovations and discuss new technology trends we can expect to see in the coming years.
“The core of our technology lies in its ability to map the body’s biomedical signals, which holds the key to finding cure to challenging and, until now, incurable diseases without the use of drugs or invasive treatments. Our first product, PURE EP System, aims to address unmet needs for the treatments of arrhythmia, a disease, which goes hand in hand with the aging population. By 2020, there will be one billion people over 60 years old worldwide. Digital Silver Forum empowers innovative businesses such as ours, and we look forward to exchanging ideas with the like-minded community, which seeks to create new opportunities for economic growth in the changing demographics,” said Kenneth Londoner.
“The global population is aging at unprecedented rates, and the only way to open pathways for innovative solutions is to connect dots where they have not been connected before – across policy, finance, and technology,” said Michael Hodin, CEO of the Global Coalition on Aging, co-host of the Digital Silver Forum. “At Digital Silver, we bring together startups, business leaders, global institutions and government to identify the opportunities for entrepreneurs to meet the needs of our growing and diverse aging population.”
About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary biomedical signal processing technology designed to improve the $4.6 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has been developed to address an unmet need in a large and growing market.
The PURE EP System is a novel cardiac signal acquisition and display system, which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP System.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Click here to connect with BioSig Technologies, Inc. (OTCQB:BSGM) for an Investor Presentation